EU/3/20/2306

About

On 27 July 2020, orphan designation EU/3/20/2306 was granted by the European Commission to Provepharm S.A.S, France, for retinol palmitate for the prevention of bronchopulmonary dysplasia.

Key facts

Active substance
Retinol palmitate
Disease / condition
Prevention of bronchopulmonary dysplasia
Date of first decision
27/07/2020
Outcome
Positive
EU designation number
EU/3/20/2306

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Provepharm S.A.S.
22 Rue Marc Donadille
13013 Marseille
France
Tel: +33 4 91 08 69 30
E-mail: safety@provepharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating